24
Participants
Start Date
April 13, 2020
Primary Completion Date
November 2, 2022
Study Completion Date
November 2, 2022
eculizumab
Intravenous infusion of BCD-148 every 2 weeks
"Territorial State Budgetary Healthcare Institution Territorial Clinical Hospital", Barnaul
"State Autonomous Healthcare Institution S.V. Belyaev Kuzbass Regional Clinical Hospital", Kemerovo
"Federal State Budgetary Institution of Science Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency", Kirov
"Moscow State Budgetary Healthcare Institution S.P. Botkin Municipal Clinical Hospital of the Moscow Healthcare Department", Moscow
"Federal State Budgetary Educational Institution of Higher Education Rostov State Medical University of the Ministry of Health of the Russian Federation", Rostov-on-Don
"Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Health of the Russian Federation", Saint Petersburg
"Federal State Budgetary Educational Institution of Higher Education I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation", Saint Petersburg
"Federal State Budgetary Educational Institution of Higher Education Samara State Medical University of the Ministry of Health of the Russian Federation", Samara
"State Institution Komi Republican Cancer Clinic", Syktyvkar
"Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry of Health of the Russian Federation", Ufa
"State Autonomous Healthcare Institution of the Sverdlovsk Region Sverdlovsk Regional Clinical Hospital No. 1", Yekaterinburg
Lead Sponsor
Biocad
INDUSTRY